Peptide · Vial
BPC 157
$8910mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
EternaGen / Research use onlyPeptide · Research use only
Tesamorelin
From CA$109CAD
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.
Available to approved purchasers
Select strength
1
Documentation review pending Fulfilled in Canada Research use only
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Tesamorelin, clearly explained.
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.
Overview
Tesamorelin has meaningful human research, but it is tied to specific prescription formulations and adults with HIV-associated lipodystrophy. A research material is not interchangeable with an approved medicine.
Tesamorelin is a stabilized analogue of growth-hormone-releasing hormone. Authorized tesamorelin drug products have formulation-specific labelling for a defined population; a research material is not interchangeable with an approved medicine.- Format
- Vial
- Available strengths
- 10mg · 20mg
- Documentation
- Source review pending
Research at a glanceEstablished human evidence for a narrow, authorized drug indication
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- 44-amino-acid GHRH analogue
- Molecular weight
- 5135.9 g/mol
- Storage and handling
- Store according to the conditions printed on the vial and supplied Certificate of Analysis.
Batch documentationSource review pending
Not yet publishedSupplier-origin documentation will be published only after EternaGen verifies the source and record details.
Important research-use boundary
Tesamorelin has authorized prescription-drug formulations for a specific indication. This catalogue item is a separate research material and is not represented as an approved, substitutable or patient-ready medicine.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
HIV-associated lipodystrophy
Randomized trials studied adults living with HIV who had excess abdominal fat while receiving antiretroviral therapy.
Evidence so far: Phase 3 human evidenceQuestion 02
Visceral and liver fat
Additional trials in people living with HIV examined visceral adipose tissue and hepatic fat under defined protocols.
Evidence so far: Clinical research in a narrow populationQuestion 03
Not general weight management
Approved U.S. labelling states that tesamorelin is not indicated for weight-loss management and that formulations are not substitutable.
Evidence so far: Regulatory label boundaryProposed mechanism
How researchers are investigating the mechanism.
Tesamorelin stimulates pituitary growth-hormone release and increases downstream IGF-I. Clinical programmes measured visceral adipose tissue and metabolic or safety outcomes in carefully defined populations.
Evidence gaps
What remains unknown?
- Results should not be generalized to people without the studied HIV-associated condition.
- Long-term cardiovascular safety remains a labelled limitation of use.
- Identity, formulation and regulatory status must be verified independently; a shared compound name is not equivalence.
Primary sources
Check the original sources.
- Primary phase 3 studyFalutz et al. Tesamorelin in HIV-associated abdominal fat accumulation. JAIDS. 2010. PMID 20101189.
- Current regulatory labelU.S. FDA. EGRIFTA WR prescribing information. 2025.
- Canadian authorization recordHealth Canada Drug Product Database. EGRIFTA (tesamorelin), prescription product.
Related products
Continue comparing.
Peptide · Vial
GHK-CU
From CA$54.9950mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Peptide · Pen
MOTS-c
From CA$6410mg20mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.